Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) saw a large decrease in short interest in June. As of June 30th, there was short interest totaling 1,984 shares, a decrease of 60.4% from the June 15th total of 5,004 shares. Based on an average daily volume of 154,020 shares, the short-interest ratio is presently 0.0 days.
Tevogen Bio Trading Down 4.5%
Shares of NASDAQ TVGNW traded down $0.00 during trading hours on Wednesday, hitting $0.05. The company had a trading volume of 167,695 shares, compared to its average volume of 132,309. Tevogen Bio has a 1-year low of $0.03 and a 1-year high of $0.08. The firm’s 50 day moving average is $0.04 and its 200-day moving average is $0.04.
About Tevogen Bio
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Featured Stories
- Five stocks we like better than Tevogen Bio
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
- 2 Quantum Stocks That Could Challenge IonQ’s Leadership
- Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger
- Alphabet’s AI Spending Question Looms Over Q2 Earnings
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
